Company profile
CRISPR THERAPEUTICS AG
NASDAQ:CRSPBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| VOLAMCABTAGENE DURZIGEDLEUCEL | phase1 | — | 2 | terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (13)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04035434 | phase1_2 | terminated | 2019-07-22 | 2024-10-04 | CRISPR Therapeutics AG | A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) |
| NCT06925542 | phase1 | recruiting | 2025-03-10 | 2031-12-31 | CRISPR Therapeutics | A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease |
| NCT07804004 | phase1_2 | not_yet_recruiting | 2026-09-15 | 2029-12-30 | CRISPR Therapeutics | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease |
| NCT05643742 | phase1_2 | recruiting | 2023-03-10 | 2030-01-01 | CRISPR Therapeutics AG | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies |
| NCT04244656 | phase1 | terminated | 2020-01-22 | 2024-01-04 | CRISPR Therapeutics AG | A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma |
FDA applications (0)
No records yet.